BioNTech (BNTX) Stock Price, News & Analysis

Company Overview

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany. Through research, manufacturing and commercial activities, it serves markets in Europe, North America and other international regions. The company was co-founded by Chief Executive Officer Uğur Şahin, Chief Medical Officer Özlem Türeci and Christoph Huber.

Key Stats

• Today's Range: $97.95 to $103.00
• 50-Day Range: $89.33 to $116.57
• 52-Week Range: $79.52 to $124.00
• Volume: 1.22 million shs
• Average Volume: 1.71 million shs
• Market Capitalization: $25.00 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $126.00
• Consensus Rating: Moderate Buy

BioNTech Stock Analysis - MarketRank™

BioNTech scored higher than 85% of companies evaluated by MarketBeat, and ranked 81st out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.68, and is based on 1 strong buy rating, 12 buy ratings, 5 hold ratings, and 1 sell rating.

Upside Potential

BioNTech has a consensus price target of $126.00, representing about 27.5% upside from its current price of $98.86.

Amount of Analyst Coverage

BioNTech has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioNTech are expected to grow in the coming year, from ($6.33) to ($5.62) per share.

Price to Book Value per Share Ratio

BioNTech has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.13% of the float of BioNTech has been sold short.

Short Interest Ratio / Days to Cover

BioNTech has a short interest ratio ("days to cover") of 0.98, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioNTech has recently decreased by 8.16%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioNTech does not currently pay a dividend.

Dividend Growth

BioNTech does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.32

News Sentiment

BioNTech has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 31 news articles for BioNTech this week, compared to 7 articles on an average week.

Search Interest

17 people have searched for BNTX on MarketBeat in the last 30 days. This is an increase of 113% compared to the previous 30 days.

MarketBeat Follows

2 people have added BioNTech to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BioNTech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,493,265.00 in company stock.

Percentage Held by Insiders

19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

15.52% of the stock of BioNTech is held by institutions.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 9/14/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BNTX
• CIK: 1776985
• Web: www.biontech.com
• Phone: 49-61-31908-40
• Fax: 49-6131-908-4390
• Employees: 7,807
• Year Founded: 2008

Price Target and Rating

• Average Price Target for BioNTech: $126.00
• High Price Target: $155.00
• Low Price Target: $94.00
• Potential Upside/Downside: +27.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.68
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.29 billion
• Net Margins: -63.54%
• Pretax Margin: -62.27%
• Return on Equity: -6.86%
• Return on Assets: -6.00%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 7.85
• Quick Ratio: 7.80

Sales & Book Value

• Annual Sales: $3.25 billion
• Price / Sales: 7.70
• Cash Flow: $1.36 per share
• Price / Cash Flow: 72.45
• Book Value: $96.59 per share
• Price / Book: 1.02

Miscellaneous

• Outstanding Shares: 252,880,000
• Free Float: 204,330,000
• Market Cap: $25.00 billion
• Optionable: Optionable
• Beta: 1.29